Employees Retirement System of Texas’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$137K Hold
44,679
﹤0.01% 353
2025
Q4
$183K Hold
44,679
﹤0.01% 344
2025
Q3
$218K Hold
44,679
﹤0.01% 322
2025
Q2
$226K Hold
44,679
﹤0.01% 355
2025
Q1
$236K Hold
44,679
﹤0.01% 249
2024
Q4
$302K Hold
44,679
﹤0.01% 287
2024
Q3
$294K Sell
44,679
-5,672
-11% -$40.7K ﹤0.01% 311
2024
Q2
$378K Buy
50,351
+5,953
+13% +$51.9K ﹤0.01% 287
2024
Q1
$443K Buy
44,398
+22,000
+98% +$245K ﹤0.01% 296
2023
Q4
$221K Buy
+22,398
New +$160K ﹤0.01% 320

Other funds holding RXRX

Employees Retirement System of Texas's RXRX Position: Q1 2026 in Review

Employees Retirement System of Texas held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 44,679 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Employees Retirement System of Texas first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $443K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Employees Retirement System of Texas held 44,679 shares of Recursion Pharmaceuticals worth $137K as of Q1 2026.
  • Employees Retirement System of Texas left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Employees Retirement System of Texas's portfolio in Q1 2026, its #353 holding.
  • Employees Retirement System of Texas first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Employees Retirement System of Texas's Recursion Pharmaceuticals position peaked at $443K in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Employees Retirement System of Texas's 13F filing for Q1 2026, filed 13 May 2026.